Functional analysis and molecular targeting of aurora kinases A and B in advanced melanoma

Genes and Cancer

Volumn 1, Issue 9, 2010, Pages 952-963

  Wang, Xiaolei ^a   Moschos, Stergios J ^a   Becker, Dorothea ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Aurora kinases; Melanoma; Molecular targeting; Xenograft studies

Indexed keywords

AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; PACLITAXEL; PF 03814735; PF 3814735; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; METASTASIS POTENTIAL; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RNA INTERFERENCE; UPREGULATION;

EID: 79952860591     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910388936     Document Type: Article

References (24)

1. Trent JM. Cytogenetics of human malignant melanoma. Cancer Metastasis Rev. 1991;10:103-13.
2. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther. 2005;4:1018-29.
3. Jaeger J, Koczan D, Thiesen HJ, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in lasermicrodissected melanoma tissues. Clin Cancer Res. 2007;13:806-15.
4. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547-66.
5. Keen N, Taylor S. Mitotic drivers: inhibitors of the Aurora B Kinase. Cancer Metastasis Rev. 2009;28:185-95.
6. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008;1786:60-72.
7. Perez de Castro I, de Carcer G, Montoya G, Malumbres M. Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. Curr Opin Pharmacol. 2008;8:375-83.
8. Emanuel S, Rugg CA, Gruninger RH, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005;65:9038-46.
9. Jani JP, Arcari J, Bernardo V, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther. 2010;9:883-94.
10. Becker D, Lee PL, Rodeck U, Herlyn M. Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene. 1992;7:2303-13.
11. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med.1997;3:887-93.
12. Scrittori L, Skoufias DA, Hans F, et al. A small C-terminal sequence of Aurora B is responsible for localization and function. Mol Biol Cell. 2005;16:292-305.
13. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol. 2007;8:798-812.
14. Sourisseau T, Maniotis D, McCarthy A, et al. Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol Med. 2010;2:130-42.
15. Shimomura T, Hasako S, Nakatsuru Y, et al. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther. 2010;9:157-66.
16. Zhou Y, Dai DL, Martinka M, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005;124:1044-52.
17. Rangel J, Nosrati M, Torabian S, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008;112:144-50.
18. Conway C, Mitra A, Jewell R, et al. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapsefree survival. Clin Cancer Res. 2009;15:6939-46.
19. Moschos SJ, Dodd NR, Jukic DM, Fayewicz SL, Wang X, Becker D. Suppressing the high-level expression and function of ATM in advanced-stage melanomas does not sensitize the cells to ionizing radiation. Cancer Biol Ther. 2009;8:1815-25.
20. Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho- ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010;102:1724-30.
21. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J. 1989;8:3685-91.
22. Wang Y, Rao U, Mascari R, et al. Molecular analysis of melanoma precursor lesions. Cell Growth Differ. 1996;7:1733-40.
23. Moschos SJ, Smith AP, Mandic M, et al. SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene.2007;26:4216-25.
24. Watson-Hurst K, Becker D. The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther. 2006;5:1375-82.